(Last updated : 2026-04-16 14:40:16)
  HASHIMOTO Yasunobu
   Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine  Department of Urology
   Position   Assistant Professor
■ Published papers
1. Original article  Clinical evaluation of medical and surgical complete responses in metastatic renal cell carcinoma treated with immune checkpoint inhibitor combination therapy. 2026/04
2. Original article  Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis. 2026/03
3. Case report  Anti-melanoma differentiation-associated Gene 5 antibody-positive interstitial lung disease, Induced by enfortumab vedotin plus pembrolizumab for Advanced urothelial carcinoma. 2026/02/05
4. Original article  Impact of cytoreductive nephrectomy on immune checkpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies for metastatic renal cell carcinoma with primary kidney tumors. 2026/02
5. Original article  Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma. 2026/01
Display all(89)
■ Academic conference presentation
1. Early experience of focal therapy using high-intensity focused ultrasound in localized prostate cancer. (Poster notice,General) 2025/10/19
2. Immunotherapy outcomes and immune microenvironment profiles of patients with non-clear cell renal cell carcinoma. (Poster notice,General) 2025/09/26
3. Impact of corticosteroid administration on treatment effectiveness in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor-based combination therapy. (Poster notice,General) 2024/05/03
4. Impact of gender on the efficacy of immune checkpoint inhibitor therapy in renal cell carcinoma. (Poster notice) 2024/04/27
5. Antibiotic and proton pump inhibitor use and survival of patients receiving immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. (Poster notice) 2024/04/26
Display all(102)
■ Education
1. 1994/04~1998/03 〔Doctoral course〕〔Doctorial Course〕, Graduate School, Division of Medicine, Tokyo Women's Medical University, Completed,